Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Invesco Ltd.

Invesco Ltd. increased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 30.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,180,471 shares of the medical research company's stock after acquiring an additional 982,170 shares during the period. Invesco Ltd. owned approximately 0.71% of Edwards Lifesciences worth $309,480,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Centiva Capital LP bought a new stake in Edwards Lifesciences in the third quarter worth $295,000. Stifel Financial Corp lifted its holdings in shares of Edwards Lifesciences by 11.9% in the 3rd quarter. Stifel Financial Corp now owns 232,738 shares of the medical research company's stock worth $15,358,000 after acquiring an additional 24,731 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its position in shares of Edwards Lifesciences by 65.2% during the third quarter. Kovitz Investment Group Partners LLC now owns 23,039 shares of the medical research company's stock valued at $1,520,000 after buying an additional 9,093 shares during the period. Public Employees Retirement System of Ohio boosted its holdings in Edwards Lifesciences by 8.2% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 300,202 shares of the medical research company's stock valued at $19,810,000 after acquiring an additional 22,731 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock worth $889,050,000 after purchasing an additional 284,918 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares of the company's stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,353 shares of company stock valued at $5,197,442. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. Truist Financial dropped their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $78.55.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.77 during mid-day trading on Tuesday, reaching $70.64. The stock had a trading volume of 1,008,759 shares, compared to its average volume of 4,893,742. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The firm has a market cap of $41.53 billion, a price-to-earnings ratio of 10.13, a PEG ratio of 4.82 and a beta of 1.15. The business's fifty day moving average is $71.28 and its 200-day moving average is $70.76.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.